Johannes Hans W. Louwerenburg

Showing 1-8 of 8 articles

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

Zocca P, van der Heijden LC, Kok M, Löwik M, Hartmann M, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Knottnerus I, Doggen CJM, van Houwelingen K, von Birgelen C

November 20, 2017 | 10.4244/EIJ-D-17-00634

Coronary interventions

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial

Tandjung K, Lam MK, Sen H, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Linssen GCM, van der Palen J, Doggen CJM, von Birgelen C

July 20, 2016 | 10.4244/EIJY15M08_01

Coronary interventions

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study

Kok M, von Birgelen C, Lam MK, Löwik M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Hartmann M, Doggen CJM, van Til J, IJzerman M

April 20, 2016 | 10.4244/EIJY15M10_06

Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial

Lam MK, Tandjung K, Sen H, Basalus M, van Houwelingen K, Stoel M, Louwerenburg H, Linssen GCM, Said S, Nienhuis M, de Man F, van der Palen J, von Birgelen C

June 19, 2015 | 10.4244/EIJV11I2A32

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Löwik M, Lam MK, Sen H, Tandjung K, van Houwelingen K, de Man F, Stoel M, Louwerenburg H, Linssen GCM, Doggen CJM, von Birgelen C

March 20, 2015 | 10.4244/EIJY14M08_11

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial

Sen H, Lam MK, Tandjung K, Basalus M, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Löwik M, Linssen GCM, Said S, Nienhuis M, Verhorst P, van der Palen J, von Birgelen C

October 20, 2014 | 10.4244/EIJV10I6A117

Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents

Sen H, Tandjung K, Basalus M, L M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Nijhuis R, Nienhuis M, Verhorst P, van der Palen J, von Birgelen C

October 26, 2012 | 10.4244/EIJV8I6A104

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry

de Man F, Tandjung K, Hartmann M, van Houwelingen K, Stoel M, Louwerenburg H, Basalus M, Sen H, Löwik M, von Birgelen C

July 27, 2012 | 10.4244/EIJV8I3A52

1

Latest news

Three-year TAVI outcomes for BAV vs TAV

FREE ARTICLE - Dao Zhou et al.

January 20, 2022

Percutaneous management of left ventricular assist device outflow graft obstruction

FREE ARTICLE - Aleksandra Gasecka et al.

January 19, 2022

EuroCTO Club Consensus on Dual Lumen Microcatheters for CTO Recanalisation; Predicting Radial Crossover in ACS, the MATRIX score; DAPT duration for BRS; and more…

December 17, 2021

Lipid-rich plaque density and LDL-C in statin-treated vs statin-naïve patients

FREE ARTICLE - Rebecca Torguson et al.

January 17, 2022

Redo transcatheter mitral valve replacement in mitral annular calcification

FREE ARTICLE - Jennifer Jdaidani et al

January 13, 2022

TAVI vs SAVR in bicuspid aortic valve stenosis

FREE ARTICLE - Monil Majmundar et al.

January 12, 2022

Management of MR patients undergoing TMVI screening

FREE ARTICLE - Sebastian Ludwig et al.

January 7, 2022

Valvular disease